June 14, 2011

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

The highest risk of cytomegalovirus (CMV) disease post-transplant is in seronegative recipients who receive a kidney from a seropositive donor. In this randomized controlled trial, a vaccine resulted in production of antibodies. Among those patients subsequently transplanted, CMV viremia responded to treatment with ganciclovir more quickly in vaccinated patients.

Renal Transplantation